Corporate Governance - Management
|Highlights | Management | Board of Directors | Committee Composition | Financial Code of Ethics | Audit Committee | Compensation Committee | Communications with the Board of Directors and Non-Management Directors | Corporate Governance Principles|
|Robert J. Hugin|
Chairman and Chief Executive Officer
Robert J. Hugin has been our Chief Executive Officer since June 2010 and our Chairman since June 2011. He was previously President and Chief Operating Officer from May 2006 to June 2010, and was elected by the Board of Directors to serve as a Director in December 2001. Mr. Hugin served as Senior Vice President and Chief Financial Officer from June 1999 to May 2006. Mr. Hugin is also Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA). Previously, Mr. Hugin was a Managing Director at J.P. Morgan & Co. Inc., which he joined in 1985. He received an A.B. degree from Princeton University in 1976 and an M.B.A. from the University of Virginia in 1985, having served as a United States Marine Corps infantry officer during the intervening period. Mr. Hugin also serves on the Board of Directors of The Medicines Company, Atlantic Health System Inc. and Family Promise, a national non-profit network assisting homeless families, and is past Chairman of the HealthCare Institute of New Jersey.
|Jacqualyn A. Fouse, Ph.D.|
Executive Vice President and Chief Financial Officer
Ms. Fouse joined Celgene as Senior Vice President and Chief Financial Officer in September 2010. Previously, she had served as Chief Financial Officer at Bunge Limited, a leading global agribusiness and food company, since July 2007. Ms. Fouse served as Senior Vice President, Chief Financial Officer and Corporate Strategy at Alcon Laboratories, Inc., the world’s leading eye care company, from 2002 to 2007. Prior to Alcon, Ms. Fouse was Chief Financial Officer of the Swissair Group and Group Treasurer of Nestle. Earlier in her career she served in various financial positions with LTV Aerospace and Defense, Celanese, Alcon and Nestle. Ms. Fouse holds B.A. and M.A. degrees in Economics from the University of Texas at Arlington. She also serves as a member of the Board of Directors for the Perrigo Company and Dick’s Sporting Goods.
|Mark J. Alles|
Executive Vice President, Global Head Hematology and Oncology
Mark Alles, age 53, became the Executive Vice President and Global Head of Hematology and Oncology in December of 2012 following his promotion to Chief Commercial Officer of Celgene Corporation in January 2012. He joined Celgene in April 2004 and served as Vice President, Global Marketing until March 2009 when he became President of the Americas Region. Responsibility for operations in Japan and Asia Pacific Region was added in July 2011. Mr. Alles previously served as Vice President for the US Oncology Business Unit of Aventis Pharmaceuticals and in other commercial sales and marketing management roles over an 11 year period. After earning his B.S. degree from Lock Haven University of Pennsylvania and serving as a Captain in the United State Marine Corps, Mr. Alles started his twenty-six year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. He currently serves as a non-paid Director for Gilda’s Club NYC, and on the Healthcare Institute of New Jersey’s Board of Trustees.
|Perry A. Karsen|
CEO, Celgene Cellular Therapeutics (CCT) and EVP, Chief Operations Officer
Perry Karsen is Executive Vice President and Chief Operations Officer at Celgene Corporation. He was appointed Chief Executive Officer of Celgene Cellular Therapeutics (CCT), our placental stem cell research and development division, in May, 2013. Previously, Perry was Senior Vice President and Head of Worldwide Business Development at Celgene and was also responsible for emerging businesses as President, Asia/Pacific Region. From 2009-2010, Perry served as President and Chief Executive Officer at Pearl Therapeutics, a privately-held biotechnology company that was subsequently acquired by Astra-Zeneca. Perry also held executive roles at Human Genome Sciences, Bristol-Myers Squibb, Genentech and Abbott Laboratories. In addition, Perry was a General Partner at Pequot Ventures.
Perry is a member of the Board of Directors of the Biotechnology Industry Organization (BIO); a member of the Board of Directors of BayBio; and a member of the Board of Directors for the Life Sciences Foundation. He is also a member of the Board of Directors of Agios Pharmaceuticals.
Perry has a Masters of Management degree from Northwestern University’s Kellogg Graduate School of Management, a Masters in Teaching of Biology from Duke University, and a B.S. in Biological Sciences from the University of Illinois, Urbana.